LV12722B - PRV-1 GAME AND ITS USE - Google Patents

PRV-1 GAME AND ITS USE Download PDF

Info

Publication number: LV12722B
Authority: LV; Latvia
Prior art keywords: polypeptide; sequence; prv; amino acid; polynucleotide
Prior art date: 1998-10-23

Application number

LVP-01-61A

Other languages

English (en)

Latvian (lv)

Other versions

LV12722A (lv

Inventor

Heike Pahl

Original Assignee

Universitatsklinikum Freiburg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-23

Filing date

2001-05-22

Publication date

2002-01-20

2001-05-22 Application filed by Universitatsklinikum Freiburg filed Critical Universitatsklinikum Freiburg

2001-09-20 Publication of LV12722A publication Critical patent/LV12722A/xx

2002-01-20 Publication of LV12722B publication Critical patent/LV12722B/en

Links

108090000623 proteins and genes Proteins 0.000 title abstract description 42
101000980845 Homo sapiens CD177 antigen Proteins 0.000 claims abstract description 73
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 68
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 68
229920001184 polypeptide Polymers 0.000 claims abstract description 66
239000002773 nucleotide Substances 0.000 claims abstract description 40
125000003729 nucleotide group Chemical group 0.000 claims abstract description 40
238000000034 method Methods 0.000 claims abstract description 25
102100024209 CD177 antigen Human genes 0.000 claims description 61
150000001413 amino acids Chemical class 0.000 claims description 31
108091033319 polynucleotide Proteins 0.000 claims description 31
102000040430 polynucleotide Human genes 0.000 claims description 31
239000002157 polynucleotide Substances 0.000 claims description 31
239000012634 fragment Substances 0.000 claims description 25
208000008601 Polycythemia Diseases 0.000 claims description 13
108020004511 Recombinant DNA Proteins 0.000 claims description 12
239000003102 growth factor Substances 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
210000001185 bone marrow Anatomy 0.000 claims description 9
239000000546 pharmaceutical excipient Substances 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
206010033661 Pancytopenia Diseases 0.000 claims description 6
238000001514 detection method Methods 0.000 claims description 5
238000003757 reverse transcription PCR Methods 0.000 claims description 5
238000003018 immunoassay Methods 0.000 claims description 4
108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
239000013604 expression vector Substances 0.000 claims description 2
238000000338 in vitro Methods 0.000 claims description 2
238000001727 in vivo Methods 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 9
238000003556 assay Methods 0.000 claims 1
230000017531 blood circulation Effects 0.000 claims 1
210000000777 hematopoietic system Anatomy 0.000 claims 1
238000002331 protein detection Methods 0.000 claims 1
229940024606 amino acid Drugs 0.000 description 27
235000001014 amino acid Nutrition 0.000 description 27
239000000203 mixture Substances 0.000 description 23
102000004169 proteins and genes Human genes 0.000 description 23
235000018102 proteins Nutrition 0.000 description 22
210000003714 granulocyte Anatomy 0.000 description 16
239000013598 vector Substances 0.000 description 14
108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
230000003394 haemopoietic effect Effects 0.000 description 13
241001430294 unidentified retrovirus Species 0.000 description 12
210000003013 erythroid precursor cell Anatomy 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
230000014509 gene expression Effects 0.000 description 11
229940079593 drug Drugs 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000002609 medium Substances 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
238000009396 hybridization Methods 0.000 description 7
239000000523 sample Substances 0.000 description 7
108020004414 DNA Proteins 0.000 description 6
238000000636 Northern blotting Methods 0.000 description 6
201000010099 disease Diseases 0.000 description 6
239000005090 green fluorescent protein Substances 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
239000012528 membrane Substances 0.000 description 6
230000004071 biological effect Effects 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
239000002243 precursor Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
108020005544 Antisense RNA Proteins 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
230000000692 anti-sense effect Effects 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
230000000925 erythroid effect Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
108020004999 messenger RNA Proteins 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
208000032027 Essential Thrombocythemia Diseases 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
208000014767 Myeloproliferative disease Diseases 0.000 description 2
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000016507 interphase Effects 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
239000008274 jelly Substances 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
230000005855 radiation Effects 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
101150072531 10 gene Proteins 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010018690 Granulocytosis Diseases 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
206010041660 Splenomegaly Diseases 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000004720 fertilization Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
208000004235 neutropenia Diseases 0.000 description 1
230000003448 neutrophilic effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
-1 secondary antibodies Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
238000012546 transfer Methods 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
229940116269 uric acid Drugs 0.000 description 1
102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Biochemistry (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

LVP-01-61A 1998-10-23 2001-05-22 PRV-1 GAME AND ITS USE LV12722B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19849044A DE19849044A1 (de)	1998-10-23	1998-10-23	Das Gen PRV-1 und dessen Verwendung
PCT/EP1999/007238 WO2000024886A1 (de)	1998-10-23	1999-09-30	Das gen prv-1 und dessen verwendung

Publications (2)

Publication Number	Publication Date
LV12722A LV12722A (lv)	2001-09-20
LV12722B true LV12722B (en)	2002-01-20

Family

ID=7885492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-01-61A LV12722B (en)	1998-10-23	2001-05-22	PRV-1 GAME AND ITS USE

Country Status (28)

Country	Link
US (2)	US6686153B1 (no)
EP (1)	EP1123392B1 (no)
JP (1)	JP2002528077A (no)
KR (1)	KR20010080883A (no)
CN (1)	CN1190491C (no)
AT (1)	ATE348109T1 (no)
AU (1)	AU771772B2 (no)
BG (1)	BG105460A (no)
BR (1)	BR9915537A (no)
CA (1)	CA2349211A1 (no)
CZ (1)	CZ20011430A3 (no)
DE (2)	DE19849044A1 (no)
EA (1)	EA200100440A1 (no)
EE (1)	EE200100234A (no)
HR (1)	HRP20010294A2 (no)
HU (1)	HUP0104954A3 (no)
IL (1)	IL142664A0 (no)
LT (1)	LT4877B (no)
LV (1)	LV12722B (no)
MX (1)	MXPA01004035A (no)
NO (1)	NO20011961L (no)
NZ (1)	NZ510970A (no)
PL (1)	PL347413A1 (no)
SI (1)	SI20585A (no)
SK (1)	SK5402001A3 (no)
WO (1)	WO2000024886A1 (no)
YU (1)	YU29801A (no)
ZA (1)	ZA200103210B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2000036102A2 (en) *	1998-12-16	2000-06-22	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE19947010A1 (de) *	1999-09-30	2001-04-05	Universitaetsklinikum Freiburg	Das Gen PRV-1 und dessen Verwendung
AU2008307643B9 (en)	2007-09-28	2014-04-17	Intrexon Corporation	Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998050552A1 (en) *	1997-05-06	1998-11-12	Zymogenetics, Inc.	Novel tumor antigens

1998
- 1998-10-23 DE DE19849044A patent/DE19849044A1/de not_active Withdrawn
1999
- 1999-09-30 US US09/830,189 patent/US6686153B1/en not_active Expired - Fee Related
- 1999-09-30 EA EA200100440A patent/EA200100440A1/ru unknown
- 1999-09-30 NZ NZ510970A patent/NZ510970A/xx unknown
- 1999-09-30 YU YU29801A patent/YU29801A/sh unknown
- 1999-09-30 EP EP99947439A patent/EP1123392B1/de not_active Expired - Lifetime
- 1999-09-30 EE EEP200100234A patent/EE200100234A/xx unknown
- 1999-09-30 HU HU0104954A patent/HUP0104954A3/hu unknown
- 1999-09-30 PL PL99347413A patent/PL347413A1/xx not_active Application Discontinuation
- 1999-09-30 CA CA002349211A patent/CA2349211A1/en not_active Abandoned
- 1999-09-30 KR KR1020017005025A patent/KR20010080883A/ko not_active Application Discontinuation
- 1999-09-30 CZ CZ20011430A patent/CZ20011430A3/cs unknown
- 1999-09-30 MX MXPA01004035A patent/MXPA01004035A/es unknown
- 1999-09-30 AU AU60883/99A patent/AU771772B2/en not_active Ceased
- 1999-09-30 CN CNB998124834A patent/CN1190491C/zh not_active Expired - Fee Related
- 1999-09-30 JP JP2000578440A patent/JP2002528077A/ja active Pending
- 1999-09-30 SI SI9920078A patent/SI20585A/sl not_active IP Right Cessation
- 1999-09-30 BR BR9915537-0A patent/BR9915537A/pt not_active IP Right Cessation
- 1999-09-30 DE DE59914061T patent/DE59914061D1/de not_active Expired - Lifetime
- 1999-09-30 WO PCT/EP1999/007238 patent/WO2000024886A1/de active IP Right Grant
- 1999-09-30 SK SK540-2001A patent/SK5402001A3/sk unknown
- 1999-09-30 AT AT99947439T patent/ATE348109T1/de not_active IP Right Cessation
- 1999-09-30 IL IL14266499A patent/IL142664A0/xx unknown
2001
- 2001-04-19 ZA ZA200103210A patent/ZA200103210B/xx unknown
- 2001-04-20 NO NO20011961A patent/NO20011961L/no not_active Application Discontinuation
- 2001-04-20 BG BG105460A patent/BG105460A/xx unknown
- 2001-04-23 HR HR20010294A patent/HRP20010294A2/hr not_active Application Discontinuation
- 2001-05-22 LT LT2001055A patent/LT4877B/lt not_active IP Right Cessation
- 2001-05-22 LV LVP-01-61A patent/LV12722B/en unknown
2003
- 2003-12-05 US US10/727,619 patent/US20040259110A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR9915537A (pt)	2001-11-13
DE19849044A1 (de)	2000-04-27
BG105460A (en)	2002-06-28
CN1190491C (zh)	2005-02-23
US20040259110A1 (en)	2004-12-23
NO20011961L (no)	2001-06-21
CZ20011430A3 (cs)	2001-08-15
EE200100234A (et)	2002-08-15
KR20010080883A (ko)	2001-08-25
SK5402001A3 (en)	2001-09-11
CN1324403A (zh)	2001-11-28
YU29801A (sh)	2005-07-19
NO20011961D0 (no)	2001-04-20
HUP0104954A3 (en)	2004-07-28
EP1123392B1 (de)	2006-12-13
LT2001055A (en)	2001-10-25
IL142664A0 (en)	2002-03-10
WO2000024886A1 (de)	2000-05-04
LV12722A (lv)	2001-09-20
LT4877B (lt)	2002-01-25
CA2349211A1 (en)	2000-05-04
HRP20010294A2 (en)	2002-06-30
EA200100440A1 (ru)	2001-10-22
MXPA01004035A (es)	2003-03-10
AU771772B2 (en)	2004-04-01
SI20585A (sl)	2001-12-31
JP2002528077A (ja)	2002-09-03
DE59914061D1 (de)	2007-01-25
EP1123392A1 (de)	2001-08-16
ZA200103210B (en)	2002-08-14
HUP0104954A2 (hu)	2002-04-29
ATE348109T1 (de)	2007-01-15
PL347413A1 (en)	2002-04-08
US6686153B1 (en)	2004-02-03
NZ510970A (en)	2003-06-30
AU6088399A (en)	2000-05-15

Publication	Publication Date	Title
US7696150B2 (en)	2010-04-13	Modulation of the activity of an interleukin 17 receptor-related protein, EVI27, and uses thereof
JP2002516103A (ja)	2002-06-04	インターロイキン２１およびインターロイキン２２
JP2001524814A (ja)	2001-12-04	２８種類のヒト分泌タンパク質
JP2005218453A (ja)	2005-08-18	８７個のヒト分泌タンパク質
JP2001524313A (ja)	2001-12-04	哺乳類のサイトカイン様ポリペプチド−１０
JP2001521383A (ja)	2001-11-06	２０個のヒト分泌タンパク質
US5858701A (en)	1999-01-12	DNA encoding an insulin receptor substrate
WO2000042189A9 (en)	2001-10-04	Interleukin-20
WO2011091716A9 (zh)	2012-08-16	表皮生长因子受体变异体
US6686153B1 (en)	2004-02-03	PRV-1 gene and the use thereof
AU7699098A (en)	1998-12-30	Selective induction of cell death by delivery of amino-terminal interleukin-1-alpha pro-piece polypeptide
EP0860447B1 (en)	2007-07-18	Hematopoietic stem cell growth factor (scgf)
AU1132401A (en)	2001-04-30	The prv-1 gene and use thereof
KR100260272B1 (ko)	2000-07-01	Tpo활성을 갖는 단백질의 아미노산을 코딩하는 염기 서열을 포함하는 dna
JP2002502601A (ja)	2002-01-29	樹状富化分泌リンパ球活性化分子
WO2012048667A1 (zh)	2012-04-19	表皮生长因子受体的外显子缺失变异体
JP2008527986A (ja)	2008-07-31	炎症及び／又は自己免疫疾患における可溶性ｃｄ１６４の使用
KR20010092800A (ko)	2001-10-27	펩타이드
Deshpande et al.	1999	Structural abnormalities in the G-CSF receptor in severe congenital neutropenia
WO2001000664A2 (en)	2001-01-04	Secreted alpha-helical protein-36